Get the Stockscreener App
4.4235
4.29%
-0.1965
Cardiff Oncology Inc stock is traded at $4.4235, with a volume of 942.50K.
It is down -4.29% in the last 24 hours and up +7.59% over the past month.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
See More
Previous Close:
$4.62
Open:
$4.58
24h Volume:
942.50K
Relative Volume:
0.46
Market Cap:
$307.34M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-4.7565
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
+9.73%
1M Performance:
+7.59%
6M Performance:
+106.64%
1Y Performance:
+136.47%
1-Day Range:
$4.25
$4.64
1-Week Range:
$3.78
$4.8299
52-Week Range:
$1.63
$6.42
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
4.425 | 307.34M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.46 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.17 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Cardiff Oncology Inc (CRDF) Beta Value: Understanding the Market Risk - The News Heater
Get in on Cardiff Oncology Inc’s (CRDF) buy-in window today! - SETE News
Cardiff Oncology Inc (CRDF) Stock: A Year of Stock Market Dynamics - The InvestChronicle
BlackRock, Inc. Expands Stake in Cardiff Oncology Inc. - GuruFocus.com
Quarterly Snapshot: Quick and Current Ratios for Cardiff Oncology Inc (CRDF) - The Dwinnex
Analysts review Cardiff Oncology Inc’s rating - Knox Daily
Cardiff Oncology Inc (CRDF)’s results reveal risk - US Post News
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
HB Wealth Management LLC Invests $105,000 in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Assenagon Asset Management S.A. Sells 203,292 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Cardiff Oncology, Inc. (NASDAQ:CRDF) Position Boosted by Barclays PLC - Defense World
If You Don’t Buy Cardiff Oncology Inc (NASDAQ: CRDF) Now, You’ll Kick Yourself Later - Stocks Register
Jane Street Group LLC Cuts Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 39,542 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology updates bylaws, changes fiscal year - Investing.com India
Cardiff Oncology Inc (NASDAQ: CRDF) Is A Buzzing Hot Stock - Stocks Register
Cardiff Oncology updates bylaws, changes fiscal year By Investing.com - Investing.com South Africa
State Street Corp Purchases 27,628 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 21.6% - MarketBeat
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - GlobeNewswire
Institutions along with individual investors who hold considerable shares inCardiff Oncology, Inc. (NASDAQ:CRDF) come under pressure; lose 27% of holdings value - Simply Wall St
While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownership - Yahoo Finance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Cardiff Oncology CFO James Levine purchases $36,725 in shares By Investing.com - Investing.com Canada
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update - MarketBeat
Piper Sandler Boosts Cardiff Oncology (NASDAQ:CRDF) Price Target to $10.00 - Defense World
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
Cardiff Oncology price target raised to $10 from $7 at Piper Sandler - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Cardiff Oncology director Gary Pace buys $940,199 in stock By Investing.com - Investing.com South Africa
Cardiff Oncology director Gary Pace buys $940,199 in stock - Investing.com
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning - Seeking Alpha
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - MSN
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - Yahoo Finance
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - Yahoo Finance
Cardiff value doubles on first-line colorectal cancer data - The Pharma Letter
Cardiff Oncology Reports Promising Phase 2 Trial Results - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Stock Quotes, Forecast and News Summary - Benzinga
Cardiff shares crest on first-line colorectal cancer response data - FirstWord Pharma
Cardiff Oncology: Beats Standard Of Care In First-Line Metastatic Colorectal Cancer - Seeking Alpha
Cardiff Aims To Change Standard Of Care For Some Colorectal Cancers - News & Insights
In midstage colorectal cancer trial, Cardiff's KRAS candidate linked to 64% response rate at higher dose - Fierce Biotech
What's Going On With Cardiff Oncology Stock On Tuesday? - AOL
Cardiff stock soars on onvansertib data, $40M direct offering - MSN
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):